PL2571863T3 - Sole nilotynibu i ich postacie krystaliczne - Google Patents
Sole nilotynibu i ich postacie krystaliczneInfo
- Publication number
- PL2571863T3 PL2571863T3 PL11728501T PL11728501T PL2571863T3 PL 2571863 T3 PL2571863 T3 PL 2571863T3 PL 11728501 T PL11728501 T PL 11728501T PL 11728501 T PL11728501 T PL 11728501T PL 2571863 T3 PL2571863 T3 PL 2571863T3
- Authority
- PL
- Poland
- Prior art keywords
- crystalline forms
- nilotinib salts
- nilotinib
- salts
- crystalline
- Prior art date
Links
- 150000004930 Nilotinib derivatives Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C229/24—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having more than one carboxyl group bound to the carbon skeleton, e.g. aspartic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/25—Sulfonic acids having sulfo groups bound to carbon atoms of rings other than six-membered aromatic rings of a carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
- C07C309/30—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings of six-membered aromatic rings substituted by alkyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
- C07C53/126—Acids containing more than four carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
- C07C55/02—Dicarboxylic acids
- C07C55/06—Oxalic acid
- C07C55/07—Salts thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
- C07C55/02—Dicarboxylic acids
- C07C55/08—Malonic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
- C07C55/02—Dicarboxylic acids
- C07C55/12—Glutaric acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
- C07C55/02—Dicarboxylic acids
- C07C55/14—Adipic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
- C07C55/22—Tricarboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
- C07C57/13—Dicarboxylic acids
- C07C57/15—Fumaric acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/42—Unsaturated compounds containing hydroxy or O-metal groups
- C07C59/48—Unsaturated compounds containing hydroxy or O-metal groups containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C62/00—Compounds having carboxyl groups bound to carbon atoms of rings other than six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C62/02—Saturated compounds containing hydroxy or O-metal groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (16)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US35677110P | 2010-06-21 | 2010-06-21 | |
| US35946910P | 2010-06-29 | 2010-06-29 | |
| US36006410P | 2010-06-30 | 2010-06-30 | |
| US36169110P | 2010-07-06 | 2010-07-06 | |
| US36551010P | 2010-07-19 | 2010-07-19 | |
| US37501310P | 2010-08-18 | 2010-08-18 | |
| US37621310P | 2010-08-23 | 2010-08-23 | |
| US38042810P | 2010-09-07 | 2010-09-07 | |
| US38213610P | 2010-09-13 | 2010-09-13 | |
| US38442810P | 2010-09-20 | 2010-09-20 | |
| US39226610P | 2010-10-12 | 2010-10-12 | |
| US40530110P | 2010-10-21 | 2010-10-21 | |
| US41020210P | 2010-11-04 | 2010-11-04 | |
| US201161434561P | 2011-01-20 | 2011-01-20 | |
| PCT/US2011/041242 WO2011163222A1 (en) | 2010-06-21 | 2011-06-21 | Nilotinib salts and crystalline forms thereof |
| EP11728501.5A EP2571863B1 (en) | 2010-06-21 | 2011-06-21 | Nilotinib salts and crystalline forms thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2571863T3 true PL2571863T3 (pl) | 2016-03-31 |
Family
ID=44310310
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL11728501T PL2571863T3 (pl) | 2010-06-21 | 2011-06-21 | Sole nilotynibu i ich postacie krystaliczne |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US8937082B2 (pl) |
| EP (2) | EP2966072A3 (pl) |
| JP (1) | JP5894153B2 (pl) |
| KR (1) | KR20130042498A (pl) |
| CA (1) | CA2803559A1 (pl) |
| ES (1) | ES2555263T3 (pl) |
| HK (1) | HK1218913A1 (pl) |
| HR (1) | HRP20151324T1 (pl) |
| PL (1) | PL2571863T3 (pl) |
| WO (1) | WO2011163222A1 (pl) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2648519A4 (en) * | 2010-11-26 | 2014-04-30 | Hetero Research Foundation | NEW POLYMORPH OF NILOTINIB HYDROCHLORIDE |
| AR086913A1 (es) * | 2011-06-14 | 2014-01-29 | Novartis Ag | 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]-amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluoro-metil)-fenil]-benzamida amorfa, forma de dosificacion que la contiene y metodo para prepararlas |
| ES2564969T3 (es) * | 2012-02-09 | 2016-03-30 | Natco Pharma Limited | Proceso para la preparación de clorhidrato de nilotinib |
| US9061028B2 (en) | 2012-02-15 | 2015-06-23 | Natco Pharma Limited | Process for the preparation of Nilotinib |
| US9376419B2 (en) | 2012-10-15 | 2016-06-28 | Apotex Inc. | Solid forms of nilotinib hydrochloride |
| US9567317B2 (en) | 2012-10-19 | 2017-02-14 | Basf Se | Multicomponent crystalline system comprising nilotinib and selected co-crystal formers |
| JP2016522182A (ja) | 2013-04-24 | 2016-07-28 | ドクター レディズ ラボラトリーズ リミテッド | ニロチニブ塩酸塩の多形形態 |
| WO2015092624A1 (en) | 2013-12-16 | 2015-06-25 | Ranbaxy Laboratories Limited | Nilotinib mono-oxalate and its crystalline form |
| WO2016020891A1 (en) | 2014-08-08 | 2016-02-11 | Dr. Reddy’S Laboratories Limited | Process for the preparation of polymorphic forms of nilotinib |
| CA2964198C (en) | 2014-10-16 | 2023-03-14 | Apotex Inc. | Solid forms of nilotinib hydrochloride |
| CN106478603B (zh) * | 2015-08-25 | 2021-01-01 | 江苏豪森药业集团有限公司 | 尼洛替尼盐酸盐的新晶型及其制备方法和医药用途 |
| WO2017129694A1 (en) | 2016-01-26 | 2017-08-03 | Farma Grs, D.O.O. | Nilotinib dinitrate (v) and crystalline forms thereof |
| US10640487B2 (en) * | 2016-03-14 | 2020-05-05 | Teva Pharmaceuticals Usa, Inc. | Solid state forms of Nilotinib salts |
| CA3041134A1 (en) * | 2016-10-28 | 2018-05-03 | Apotex Inc. | Novel salts of nilotinib and crystalline forms thereof |
| EP3404025B1 (en) * | 2017-05-16 | 2019-12-04 | F.I.S.- Fabbrica Italiana Sintetici S.p.A. | Process for the preparation of pure nilotinib and its salt |
| CZ2017821A3 (cs) | 2017-12-20 | 2019-07-03 | Zentiva, K.S. | Léková forma obsahující krystalický nilotinib |
| TWI831259B (zh) | 2018-06-15 | 2024-02-01 | 漢達生技醫藥股份有限公司 | 包含達沙替尼十二烷基硫酸鹽組合物的膠囊 |
| US12065426B2 (en) | 2018-11-05 | 2024-08-20 | Laurus Labs Limited | Crystalline form of nilotinib hydrochloride, process for its preparation and pharmaceutical composition containing the same |
| CN113573712A (zh) | 2019-02-18 | 2021-10-29 | 斯莱班克制药有限责任公司 | 尼洛替尼的药物组合物 |
| US20230075170A1 (en) * | 2020-02-15 | 2023-03-09 | Cipla Limited | Novel salts of nilotinib and polymorphic forms thereof |
| WO2023285981A1 (en) * | 2021-07-15 | 2023-01-19 | Torrent Pharmaceuticals Limited | Stable pharmaceutical liquid composition of nilotinib |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0215676D0 (en) * | 2002-07-05 | 2002-08-14 | Novartis Ag | Organic compounds |
| GT200600316A (es) * | 2005-07-20 | 2007-04-02 | Sales de 4-metilo-n-(3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo)-3-(4-piridina-3-ilo-pirimidina-2-iloamino)- benzamida. | |
| GT200600315A (es) * | 2005-07-20 | 2007-03-19 | Formas cristalinas de 4-metilo-n-[3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo]-3-(4-pyridina-3-ilo-pirimidina-2-iloamino)-benzamida | |
| HU227474B1 (en) | 2005-12-20 | 2011-07-28 | Richter Gedeon Nyrt | Process for industrial scale production of high purity donepezil hydrochloride polymorph i. |
| WO2010054056A2 (en) * | 2008-11-05 | 2010-05-14 | Teva Pharmaceutical Industries Ltd. | Nilotinib hci crystalline forms |
| WO2011033307A1 (en) | 2009-09-17 | 2011-03-24 | Generics [Uk] Limited | Nilotinib dihydrochloride salt |
-
2011
- 2011-06-21 US US13/806,069 patent/US8937082B2/en active Active
- 2011-06-21 ES ES11728501.5T patent/ES2555263T3/es active Active
- 2011-06-21 PL PL11728501T patent/PL2571863T3/pl unknown
- 2011-06-21 HR HRP20151324TT patent/HRP20151324T1/hr unknown
- 2011-06-21 CA CA2803559A patent/CA2803559A1/en not_active Abandoned
- 2011-06-21 KR KR1020127033454A patent/KR20130042498A/ko not_active Ceased
- 2011-06-21 JP JP2013516686A patent/JP5894153B2/ja not_active Expired - Fee Related
- 2011-06-21 EP EP15165125.4A patent/EP2966072A3/en not_active Withdrawn
- 2011-06-21 EP EP11728501.5A patent/EP2571863B1/en active Active
- 2011-06-21 WO PCT/US2011/041242 patent/WO2011163222A1/en not_active Ceased
-
2014
- 2014-11-12 US US14/538,939 patent/US9090598B2/en not_active Expired - Fee Related
-
2016
- 2016-06-15 HK HK16106892.8A patent/HK1218913A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2011163222A1 (en) | 2011-12-29 |
| HRP20151324T1 (hr) | 2016-01-29 |
| EP2966072A2 (en) | 2016-01-13 |
| US8937082B2 (en) | 2015-01-20 |
| ES2555263T3 (es) | 2015-12-30 |
| EP2571863B1 (en) | 2015-09-23 |
| EP2571863A1 (en) | 2013-03-27 |
| KR20130042498A (ko) | 2013-04-26 |
| JP2013529639A (ja) | 2013-07-22 |
| EP2966072A3 (en) | 2016-02-24 |
| JP5894153B2 (ja) | 2016-03-23 |
| CA2803559A1 (en) | 2011-12-29 |
| US20150099885A1 (en) | 2015-04-09 |
| US9090598B2 (en) | 2015-07-28 |
| US20130158059A1 (en) | 2013-06-20 |
| HK1218913A1 (en) | 2017-03-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL2571863T3 (pl) | Sole nilotynibu i ich postacie krystaliczne | |
| GB201001075D0 (en) | Crystalline forms | |
| IL249056A0 (en) | Phenothiazine diaminium salts and their use | |
| DK2786756T3 (en) | Kombinationsterapi med en topoisomeraseinhibitor | |
| EP3421470B8 (de) | Substituierte 5-fluor-1h-pyrazolopyridine in kristalliner form | |
| EP2693916A4 (en) | CUSHION | |
| GB201400072D0 (en) | Implant and implant system | |
| ZA201300957B (en) | 5-chloro-4-hydroxy-1-methyl-2-oxo-n-phenyl-1,2-dihydroquinoline-3-carboxamide, salts and use thereof | |
| SI2545048T1 (sl) | Soli Raltegravirja in njegove kristalinične oblike | |
| IL222265A0 (en) | Crystalline ingenol mebutate | |
| EP2790618A4 (en) | ORAL DEVICE FOR SLEEP APNEA | |
| GB201018124D0 (en) | Polymorphs and salts | |
| EP2759294A4 (en) | FENTANYL-PERCEIVED ABSORBABLE PREPARATION AND APPROPRIATE APPARATUS THEREOF | |
| PL2578595T3 (pl) | Krystaliczna lewoizowalerylospiramycyna I | |
| ZA201209666B (en) | Salts and polymorhs of dexrabeprazole | |
| ZA201402010B (en) | Crystalline diacylhydrazine and the use thereof | |
| PT2655363T (pt) | Formas cristalinas e processos para a sua preparação | |
| GB201102647D0 (en) | Pillow | |
| TWM433166U (en) | Pillow | |
| GB201003853D0 (en) | Improvements in crystallisation | |
| GB201013511D0 (en) | Salts | |
| HU0900285D0 (en) | Rosuvastatin salts and preparation thereof | |
| HU1000498D0 (en) | New salts and preparation process thereof | |
| TWM385307U (en) | Pillow | |
| TWM400816U (en) | Pillow |